ESPOSITO, Roberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.221
EU - Europa 8.902
AS - Asia 7.877
SA - Sud America 874
Continente sconosciuto - Info sul continente non disponibili 233
AF - Africa 148
OC - Oceania 16
Totale 34.271
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.885
GB - Regno Unito 2.752
IT - Italia 2.516
CN - Cina 2.308
SG - Singapore 2.271
SE - Svezia 1.020
HK - Hong Kong 930
VN - Vietnam 736
BR - Brasile 668
DE - Germania 594
UA - Ucraina 443
FI - Finlandia 419
TR - Turchia 409
BD - Bangladesh 297
FR - Francia 294
RU - Federazione Russa 270
KR - Corea 263
IN - India 208
CA - Canada 177
BG - Bulgaria 146
NL - Olanda 108
AR - Argentina 80
MX - Messico 76
ZA - Sudafrica 58
IQ - Iraq 55
LT - Lituania 55
ID - Indonesia 50
PL - Polonia 46
IE - Irlanda 41
PK - Pakistan 40
IR - Iran 39
JP - Giappone 39
ES - Italia 33
AE - Emirati Arabi Uniti 31
CO - Colombia 31
BE - Belgio 29
PH - Filippine 26
EC - Ecuador 24
EU - Europa 24
IL - Israele 23
UZ - Uzbekistan 21
CL - Cile 20
CR - Costa Rica 19
MY - Malesia 19
AT - Austria 17
CH - Svizzera 17
EG - Egitto 17
JM - Giamaica 16
JO - Giordania 16
PE - Perù 16
SA - Arabia Saudita 16
VE - Venezuela 16
MA - Marocco 15
AU - Australia 13
DZ - Algeria 12
KE - Kenya 12
TH - Thailandia 12
GR - Grecia 10
RO - Romania 10
RS - Serbia 10
CZ - Repubblica Ceca 9
HN - Honduras 9
KZ - Kazakistan 9
PA - Panama 9
PY - Paraguay 9
DK - Danimarca 8
DO - Repubblica Dominicana 8
KG - Kirghizistan 8
PT - Portogallo 7
TN - Tunisia 7
AZ - Azerbaigian 6
NO - Norvegia 6
SI - Slovenia 6
TW - Taiwan 6
AL - Albania 5
ET - Etiopia 5
GE - Georgia 5
KW - Kuwait 5
LV - Lettonia 5
SK - Slovacchia (Repubblica Slovacca) 5
UY - Uruguay 5
AM - Armenia 4
EE - Estonia 4
GT - Guatemala 4
LB - Libano 4
MD - Moldavia 4
NI - Nicaragua 4
NP - Nepal 4
OM - Oman 4
QA - Qatar 4
SN - Senegal 4
BO - Bolivia 3
BY - Bielorussia 3
CI - Costa d'Avorio 3
MG - Madagascar 3
NZ - Nuova Zelanda 3
PR - Porto Rico 3
SY - Repubblica araba siriana 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BH - Bahrain 2
Totale 34.025
Salva come PNG Salva come JPEG
Città #
Southend 2.066
Santa Clara 1.620
Singapore 1.488
Ashburn 1.364
Fairfield 1.105
Woodbridge 1.011
Chandler 918
Hong Kong 903
Jacksonville 797
Hefei 787
Houston 679
Dearborn 572
Nyköping 514
San Jose 499
Wilmington 495
Beijing 487
Ann Arbor 449
Seattle 388
Cambridge 374
Council Bluffs 354
London 341
Los Angeles 327
Chicago 298
Helsinki 263
Milan 259
Seoul 249
Izmir 245
New York 221
Ho Chi Minh City 214
The Dalles 195
Rome 192
Hanoi 167
Princeton 147
Buffalo 144
Dallas 138
Sofia 138
Eugene 135
Modena 119
San Diego 119
Salt Lake City 118
Lauterbourg 111
Des Moines 105
Shanghai 96
Naples 89
Frankfurt am Main 88
Moscow 80
São Paulo 69
Tampa 64
Munich 58
Elk Grove Village 52
Orem 49
Boardman 48
Bologna 46
Columbus 46
Da Nang 46
Toronto 46
Montreal 45
Philadelphia 45
Palermo 43
Bari 38
Florence 37
Nanjing 37
Warsaw 37
Guangzhou 35
Bremen 34
Haiphong 33
Atlanta 32
Dublin 32
Chennai 31
Tokyo 30
Brooklyn 29
Kent 29
Redwood City 29
Mexico City 28
Sterling 28
Verona 28
Mumbai 27
Turin 27
Ottawa 26
Johannesburg 25
Catania 24
Brescia 23
Brussels 23
Kunming 23
Amsterdam 22
Augusta 22
Detroit 22
Jakarta 22
San Mateo 22
Baghdad 21
Boston 21
Falkenstein 21
Norwalk 21
Phoenix 21
Memphis 20
Miano 20
Parma 20
Lancaster 19
Miami 19
Rio de Janeiro 19
Totale 23.202
Salva come PNG Salva come JPEG
Nome #
Un raro caso di prostatite da Candida albicans, Candida krusei ed Enterococcus fecium 1.895
Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis 511
Nonalcoholic Fatty Liver Disease in HIV-Infected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors 428
Outcome, incidence, and timing of infectious complications in small bowel and multivisceral organ transplantation patients 409
A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease. 393
Identification and characterization of an aspartyl protease from Cryptococcus neoformans 388
Multidisciplinary approach to the treatment of metabolic and morphologic alterations of HIV-related lipodystrophy 367
Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study 366
MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients 358
The human immunodeficiency virus (HIV) protease inhibitor indinavir directly affects the opportunistic fungal pathogen Cryptococcus neoformans 349
Metabolic disorders induced by highly active antiretroviral therapy and their relationship with vascular remodeling of the brachial artery in a population of HIV-infected patients 347
Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study 346
Gram-positive bloodstream infections in liver transplant recipients: incidence, risk factors, and impact on survival. 344
Efficacy and safety of atazanavir in patients with end-stage liver disease. 337
Alendronate treatment for osteoporosis in patients infected with human immunodeficiency virus. 336
Autologous fat transfer for the treatment of HIV-related face lipoatrophy: A long follow-up experience 325
La clinica metabolica per il trattamento della lipodistrofia 322
Fatal cytomegalovirus necrotising enteritis in a small bowel transplantation adult recipient with low pp65 antigenaemia levels 319
Mitochondrial DNA Haplogroups and Highly Active Antiretroviral Therapy–Related Lipodystrophy 319
Long-term psychometric outcomes of facial lipoatrophy therapy: Forty-eight-week observational, nonrandomized study 316
Different sensitivity to apoptosis in cells of monocytic or lymphocytic origin chronically infected with human immunodeficiency virus type-1 309
Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital 308
Facial lipohypertrophy in HIV-infected subjects who underwent autologous fat tissue transplantation. 308
Body image is a major determinant of sexual dysfunction in stable HIV-infected women. 308
Outcome, incidence, and timing of infections in small bowel/multivisceral transplantation 306
Gli ascessi epatici nei pazienti sottoposi a trapianto ortotopico di fegato 303
Alendronate reduces bone turnover in HIV-associated Osteopenia and Osteoporosis 302
Detectable HIV viral load is associated with metabolic syndrome 302
Differential Dose Adjustments of Immunosuppressants after Resuming Boosted versus Unboosted HIV-Protease Inhibitors Postliver Transplant. 301
Deregulation of the CD95/CD95L system in lymphocytes from patients with primary acute HIV infection 301
Genetic polymorphisms of Fas (CD95) and Fas ligand (CD178) influence the rise in CD4+ T cell count after antiretroviral therapy in drug-naive HIV-positive patients. 301
Features of 'CD4-exploders', HIV-positive patients with an optimal immune reconstitution after potent antiretroviral therapy 296
Autologous fat transfer for treating facial wasting in HIV body fat redistribution syndrome. 294
Brucellosis in a patient with end-stage liver disease undergoing liver transplantation: successful treatment with tigecycline. 293
Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: An international observational study 287
Applicazione della scala di valutazione, Functional indipendence Measure (FIM), per la valutazione dei programmi di riabilitazione per pazienti affetti da AIDS Dementia Complex ospiti di una casa alloggio 286
Congenital pyelectasis in children born from mothers on tenofovir containing therapy during pregnancy: report of two cases. 285
Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy 284
Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function. 283
MMP-7 promoter polymorphisms do not influence CD4+ recovery and changes in plasma viral load during antiretroviral therapy for HIV-1 infection. 280
Quantitation of CD95 and CD95L mRNA expression in chronic and acute HIV-1 infection by competitive RT-PCR 279
Late presenters in an HIV surveillance system in Italy during the period 1992-2006. 278
Severity of lipodystrophy is associated with decreased health-related quality of life 277
Role of therapeutic drug monitoring in a patient with human immunodeficiency virus infection and end-stage liver disease undergoing orthotopic liver transplantation 275
Autologous fat transfer for treating facial wasting in HIV-related lipodystrophy: experience of 53 treated patients 274
Autologous fat transfer for the treatment of HIV-related face lipoatrophy: 1-year follow-up 273
Immunophenotype of HIV plus patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system 269
Raltegravir and enfuvirtide as a “bridge” antiretroviral therapy in kidney-tranplanted patients with HIV infection receiving everolimus and low-dose cyclosporine: a case-control study 268
Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study. 263
Psychometric evaluation of patients undergoing surgical treatment of HIV-related facial lipoatrophy 261
Prevalence of and risk factors for pubic lipoma development in HIV-infected persons 259
Body Image is a major determinant of sexual dysfunction in stable HIV-infected women. 258
Age-related comorbidities in people living with HIV 256
Artropodi vettori di agenti infettivi 256
Prospective, partially randomized, 24-week study to compare the efficacy and durability of different surgical techniques and interventions for the treatment of HIV-related facial lipoatrophy 249
Dietary evaluation and metabolic alterations in HIV-related lipodystrophy 248
Assessment of 10-year probability of a major osteoporotic fracture in HIV-infected patients using FRAX® tool algorithms. 248
Alendronate for the treatment of Osteoporosis in HIV-infected patients. 248
Association of serum vitamin D levels nd type 2 diabetes in HIV infection in the Modena cohort 248
Un caso di tubercolosi post-trapianto ortotopico di fegato: limiti dell’impiego del quantiferon-TB gold nella diagnosi della infezione tubercolare latente ed attiva 246
Bloodstream infections (BSIs) in Liver Transplant Recipients: Analisys at an Italian Tertiary-Care Hospital 245
Prevalence of secondary causes of osteoporosis among HIV infected individuals 245
CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 10(6) cells/I 245
Improving the appropriateness of antibiotic prescription in hospitals: a pilot study assessing the effectiveness of an infectious diseases specialist's consultation programme 243
Morphologic alterations in HIV infected people with lipodystropy are associated with good adherence to HAART. 232
Does lipodistrophy affect quality of life? 229
Autologous fat transfer for treating facial waisting in HIV body fat redistribution Syndrome 228
Body Image perception in HIV infected women with body fat redistribution. 227
Candidemia nosocomiale: quattro anni di esperienza in un'ospedale universitario italiano 225
Efficacy and safety of medical and surgical interventions for treating HIV-related lipodystrophy in women 222
Posttransplant Mycobacterium tuberculosis disease following liver transplantation and the need for cautious evaluation of quantiferon TB GOLD results in the transplant setting: A case report 221
Psychometric evaluation in patients undergoing fillers injections for the treatment of HIV-related facial lipoatrophy: polylactic acid versus polyacrylamide 221
Invasive pulmonary and cerebral aspergillosis in a patient with Weil's disease 220
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: The CARe study 219
First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006) 216
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1 214
Determinants of erectile dysfunction changes in HIV infected men: a prospective study. 214
Long-term follow-up of graft hypertrophy after autologous fat transfer for HIV-related face lipoatrophy (hamster syndrome 1 year later) 212
Long lasting psycho-social benefits of polyacrylamide injections for the treatment of facial lipoatrophy 212
Rituximab as treatment of posttransplant lymphoproliferative disorder in patients who underwent small bowel/multivisceral transplantation: Report of three cases 209
Pharmacokinetic interaction between amprenavir/ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation 209
Does change of the liver change the metabolism? Assessment of atazanavir pharmacokinetic profile in 7 HIV-infected patients pre- and post-liver transplantation 204
GH response to GH-releasing hormone-arginine (GHRH+Arg) is impaired in women affected by human immunodeficiency virus (HIV)-related lipodystrophy 204
È possibile un counselling HIV su internet? 202
HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3. 201
The role of virological and immunological parameters on the diagnosis of metabolic syndrome in HIV-associated lipodystrophy 200
La trasmissione verticale di HIV nell’era della HAART 200
Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: The changes in opportunistic prophylaxis study 198
Statistical agreement between ATPIII, IDF, EGIR, AACE metabolic syndrome classifications in HIV-infected patients and association with lipodystrophy 198
Validity of body image perception in women with HIV. 195
Body fat redistribution syndrome in HIV infected people is associated with good adherence to HAART 195
CD4-Guided treatment interruptions: a new possibile therapeutic strategy 194
Different dose adjustments of immunosuppresants are necessary after initiating boosted or unboosted first protease inhibitors regimen post-liver transplantation 194
Studio caso-controllo sui fattori di rischio delle infezioni micotiche nei pazienti sottoposti a trapianto ortotopico di fegato (OLT) da donatore cadavere e da donatore vivente. 192
Pathological fractures in patients with osteopenia and osteoporosis induced by antiretroviral therapy 192
Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA 190
Erectile dysfunction does not mirror sub-clinical atherosclerosis in HIV infected males. 189
La casa alloggio: ospite, centro riabilitativo o entrambi? 186
Mechanical and ultrasound-assisted liposuction for treating subcutaneous fat accumulations in HIV-related lipodystrophy: experience of 33 treated patients 183
Prevalence and risk factors of pubic lipomas in HIV-infected patients 181
Totale 28.351
Salva come PNG Salva come JPEG
Categoria #
all - tutte 125.981
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 125.981
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.881 0 0 189 246 53 85 118 177 220 134 367 292
2022/20232.854 300 261 229 240 316 467 46 288 333 55 166 153
2023/20241.739 111 139 122 176 283 151 149 199 52 60 104 193
2024/20255.789 219 94 93 387 1.230 791 461 287 658 258 619 692
2025/202610.111 674 477 893 1.237 1.715 756 1.000 489 985 828 633 424
2026/2027924 283 580 61 0 0 0 0 0 0 0 0 0
Totale 34.271